Tau, the protein that has displaced amyloid as the central target in Alzheimer's drug development, appears to damage brain cells by infiltrating their energy-producing machinery and running it backward.
A team led by Stanford Medicine researchers reports in Neuron that tau can enter mitochondria and drive electrons in the opposite direction of their normal path, a reversal that generates reactive oxygen species, cellular stress and inflammation.
